CLAIMS

1. An antibody or antigen-binding fragment thereof which binds to human IL-13, comprising:

   (a) a light chain variable region comprising the sequence given in SEQ ID NO:13 or SEQ ID NO:17;

   and

   (b) a heavy chain variable region comprising the sequence given in SEQ ID NO:14 or SEQ ID NO:18.

2. An antibody or antigen-binding fragment according to claim 1, wherein the light chain variable region comprises the sequence given in SEQ ID NO:13 and the heavy chain variable region comprises the sequence given in SEQ ID NO:14.

3. An antibody or antigen-binding fragment according to claim 1, wherein the light chain variable region comprises the sequence given in SEQ ID NO:17 and the heavy chain variable region comprises the sequence given in SEQ ID NO:18.

4. An antibody or antigen-binding fragment according to any of claims 1 to 3, wherein the antibody is a full-length antibody.

5. An antibody or antigen-binding fragment according to any of claims 1 to 3, wherein the antigen-binding fragment is a Fab, Fab', $F(ab')_2$, Fv, dsFv, scFv, or dsscFv.

6. An antibody or antigen-binding fragment according to claim 5, wherein the antigen-binding fragment is a scFv comprising the sequence given in SEQ ID NO:21 or a dsscFv comprising the sequence given in SEQ ID NO:23.

7. An isolated polynucleotide encoding an antibody or antigen-binding fragment according to any of claims 1 to 6.

8. An expression vector carrying the polynucleotide of claim 7.

9. A host cell comprising the vector as defined in claim 8.

10. A method of producing the antibody or antigen-binding fragment of any of claims 1 to 6, comprising culturing the host cell of claim 9 under conditions permitting production of the antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment produced.

11. A pharmaceutical composition comprising an antibody or antigen-binding fragment as defined in any of claims 1 to 6, and a pharmaceutically acceptable adjuvant or carrier.

12. An antibody or antigen-binding fragment as defined in any of claims 1-6, or a pharmaceutical composition as defined in claim 11, for use in the treatment of atopic dermatitis, chronic hand eczema, nasal micropolyposis or polyposis, food allergy, or eosinophilic esophagitis.

13. An antibody or antigen-binding fragment as defined in any of claims 1-6 for use in therapy.